常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.56/-4.26
|
|
企业价值
10.68B
|
| 资产负债 |
|
每股账面净值
12.52
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.90M
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/20 09:32 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |

70.845 
